14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AMBQ vs CHYM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Chime Financial, Inc. (CHYM) is the stronger overall head-to-head candidate over Ambiq Micro, Inc. (AMBQ) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AMBQ carries a Unified Composite Score of 46.9/100 (HOLD) at $44.59 (N/M Forward P/E, -36.0% operating margin), whereas CHYM carries 27.2/100 (SELL) at $34.48 (30.9x Forward P/E, 19.3% operating margin).
Composite vs. Pillar Nuance: While AMBQ currently prints a higher short-term Unified Composite Score (46.9/100 HOLD vs. CHYM 27.2/100 SELL), CHYM captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (19.3% vs. -36.0% operating margin) and revenue trajectory (+32.1% vs. +110.0% YoY).
Technical & Structure Timing Caution: AMBQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.3); meanwhile CHYM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 73.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Software - Application value chain with $12.7B market capitalization and 19.3% operating margin.
OpEx & R&D Reinvestment70.1% of Rev ($10.1B)
90D Engineering Disclosures0 Published
Investor FAQ AMBQ vs CHYM Key Questions & Quantitative Answers
As of Nov 16, 2026, Chime Financial, Inc. (CHYM) is the stronger overall head-to-head candidate over Ambiq Micro, Inc. (AMBQ) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AMBQ carries a Unified Composite Score of 46.9/100 (HOLD) at $44.59 (N/M Forward P/E, -36.0% operating margin), whereas CHYM carries 27.2/100 (SELL) at $34.48 (30.9x Forward P/E, 19.3% operating margin). Composite vs. Pillar Nuance: While AMBQ currently prints a higher short-term Unified Composite Score (46.9/100 HOLD vs. CHYM 27.2/100 SELL), CHYM captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (19.3% vs. -36.0% operating margin) and revenue trajectory (+32.1% vs. +110.0% YoY). Technical & Structure Timing Caution: AMBQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.3); meanwhile CHYM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 73.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AMBQ leads the Growth & Scale pillar: AMBQ posts +110.0% YoY revenue growth and +0.0% YoY earnings growth on $118M TTM revenue (44.8% gross margin, -36.0% operating margin), compared with CHYM at +32.1% YoY revenue growth and -33.8% YoY earnings growth on $14.3B TTM revenue (89.4% gross margin, 19.3% operating margin). Across the 3-period historical trajectory (FY2023 to FY2025), AMBQ cumulative revenue shifted -12.5% while CHYM shifted +71.1%. In operating R&D and SG&A reinvestment, AMBQ deploys 80.8% of Rev ($95M) (0 90-day corporate R&D disclosures) versus 70.1% of Rev ($10.1B) (0 disclosures) for CHYM.
CHYM screens cheaper on headline valuation multiples. AMBQ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.3x EV/Revenue (-33.8% FCF margin), whereas CHYM trades at 30.9x Forward P/E, 29.0x Trailing P/E, N/M PEG, and 0.7x EV/Revenue (15.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMBQ (-12.2% ROE) versus CHYM (5.4% ROE) capital efficiency.
In options market volatility and institutional positioning, AMBQ carries 96.5% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 2.14x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.71β · 125% Vol realized risk). By comparison, CHYM carries 50.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.22x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.45β · 36% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.